Abstract
Background
Twenty one (12 females) subjects, diagnosed with schizophrenia by a psychiatrist using ICD-10, in the ages 52.87 + 9.5 years and suffering since 24.0 ± 3.05 years were recruited into the study from a schizophrenia rehabilitation center in Bengaluru.
Methods
All subjects were taking anti-psychotic medications and were in stable state for more than a month. Psychiatric medications were kept constant during the study period. Assessments were done at three points of time: (1) baseline, (2) after one month of usual routine (pre) and (3) after five months of validated Integrated Yoga (IY) intervention (post). Validated 1 h Yoga module (consisting of asanas, pranayama, relaxation techniques and chantings) was practiced for 5 months, five sessions per week. Antipsychotic-induced side effects were assessed using Simpson Angus Scale (SAS) and Udvalg for Kliniske Undersogelser (UKU) side effect rating scale. Cognitive functions (using Trail making Test A and B), clinical symptoms and anthropometry were assessed as secondary variables. Comparisons between “pre” and “post” data was done using paired samples t-tests after subtracting baseline scores from them respectively.
Results
At the end of five months, significant reduction in drug-induced Parkinsonian symptoms (SAS score; p=0.001) and 38 items of UKU scale was observed along with significant improvement in processing speed, executive functions and negative symptoms of schizophrenia patients. No side effects of Yoga were reported.
Conclusions
The present study provides preliminary evidence for usefulness of Integrated Yoga intervention in managing anti-psychotic-induced side effects.
Acknowledgments:
We are thankful to Dr Ranganathan for his support and to all the patients who cooperated during this research.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
[1] Arana GW. Overview of side effects caused by typical anti-psychotics. J Clin Psychiatry. 2000;61:5–11.Search in Google Scholar
[2] Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol. 2001;6:153–62.10.1097/00004850-200105000-00004Search in Google Scholar
[3] Usher K, Foster K, Park T. The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management. J Psychiatr Ment Health Nurs. 2006;13:730–4.10.1111/j.1365-2850.2006.01026.xSearch in Google Scholar
[4] Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry. 1999;174:44–51.10.1192/S0007125000298103Search in Google Scholar
[5] Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol. 1996;6:13–20.10.1016/0924-977X(96)00010-7Search in Google Scholar
[6] Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233–56.10.1093/oxfordjournals.schbul.a033376Search in Google Scholar PubMed
[7] McEvoy JP, McCue M, Spring B, Mohs RC, Lavori PW, Farr RM. Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers. Am J Psychiatry. 1987;144:573–7.10.1176/ajp.144.5.573Search in Google Scholar PubMed
[8] Feinberg M. The problem of anticholergic adverse effect in older patients. Drug Aging. 1993;3:335–48.10.2165/00002512-199303040-00004Search in Google Scholar PubMed
[9] Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161:116–24.10.1176/appi.ajp.161.1.116Search in Google Scholar PubMed
[10] Woolery A, Myers H, Sternlieb B, Zeltzer L. A yoga intervention for young adults with elevated symptoms of depression. Altern Ther Health Med. 2004;10:60–3.Search in Google Scholar
[11] Vancampfort D, Vansteelandt K, Scheewe T, Probst M, Knapen J, De Herdt A, et al. Yoga in schizophrenia: a systematic review of randomised controlled trials. Acta Psychiatr Scand. 2012;126:12–20.10.1111/j.1600-0447.2012.01865.xSearch in Google Scholar PubMed
[12] Duraiswamy G, Thirthalli J, Nagendra HR, Gangadhar BN. Yoga therapy as an add‐on treatment in the management of patients with schizophrenia – a randomized controlled trial. Acta Psychiatr Scand. 2007;116:226–32.10.1111/j.1600-0447.2007.01032.xSearch in Google Scholar PubMed
[13] Varambally S, Gangadhar BN, Thirthalli J, Jagannathan A, Kumar S, Venkatasubramanian G, et al. Therapeutic efficacy of add-on yogasana intervention in stabilized outpatient schizophrenia: randomized controlled comparison with exercise and waitlist. Indian J Psychiatry. 2012;54:227.10.4103/0019-5545.102414Search in Google Scholar PubMed PubMed Central
[14] Manjunath RB, Varambally S, Thirthalli J, Basavaraddi IV, Gangadhar BN. Efficacy of yoga as an add-on treatment for in-patients with functional psychotic disorder. Indian J Psychiatry. 2013;55:374.10.4103/0019-5545.116314Search in Google Scholar PubMed PubMed Central
[15] Visceglia E, Lewis S. Yoga therapy as an adjunctive treatment for schizophrenia: a randomized, controlled pilot study. J Altern Complement Med. 2011;17:601–7.10.1089/acm.2010.0075Search in Google Scholar PubMed
[16] Thirthalli J, Duraiswamy G, Varambally S, Nagendra HR, Gangadhar BN. Yoga as an add-on treatment in the management of schizophrenia: a randomized controlled trial. Ann Gen Psychiatry. 2006;5:84.10.1186/1744-859X-5-S1-S84Search in Google Scholar
[17] Jayaram N, Varambally S, Behere RV, Venkatasubramanian G, Arasappa R, Christopher R, et al. Effect of yoga therapy on plasma oxytocin and facial emotion recognition deficits in patients of schizophrenia. Indian J Psychiatry. 2013 Jul;55:S409.10.4103/0019-5545.116318Search in Google Scholar PubMed PubMed Central
[18] Hall E, Verheyden G, Ashburn A. Effect of a yoga program on an individual with Parkinson’s disease: a single-subject design. Disabil Rehabil. 2011;33:1483–9.10.3109/09638288.2010.529233Search in Google Scholar PubMed
[19] Innes KE, Bourguignon C, Taylor AG. Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review. J Am Board Fam Pract. 2005;18:491–519.10.3122/jabfm.18.6.491Search in Google Scholar PubMed
[20] Ikai S, Uchida H, Suzuki T, Tsunoda K, Mimura M, Fujii Y. Effects of yoga therapy on postural stability in patients with schizophrenia-spectrum disorders: a single-blind randomized controlled trial. J Psychiatr Res. 2013;47:1744–50.10.1016/j.jpsychires.2013.07.017Search in Google Scholar PubMed
[21] Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol. 2005 Mar 17;5:5.10.1186/1471-2377-5-5Search in Google Scholar PubMed PubMed Central
[22] Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients. Acta Psychiatr Scand. 1987;76:1–00.10.1111/j.1600-0447.1987.tb10566.xSearch in Google Scholar PubMed
[23] Zalonis I, Kararizou E, Triantafyllou NI, Kapaki E, Papageorgiou S, Sgouropoulos PE, et al. A normative study of the trail making test A and B in Greek adults. Clin Neuropsychol. 2008 Sep 1;22:842–50.10.1080/13854040701629301Search in Google Scholar
[24] Norman RM, Malla AK, Cortese L, Diaz F. A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophr Res. 1996 Mar 31;19:73–85.10.1016/0920-9964(95)00055-0Search in Google Scholar
[25] Govindaraj R, Varambally S, Sharma M, Gangadhar BN. Designing and validation of a yoga-based intervention for schizophrenia. Int Rev Psychiatry. 2016;28:323–6.10.3109/09540261.2016.1151404Search in Google Scholar PubMed
[26] Bhatia T, Agarwal A, Shah G, Wood J, Richard J, Gur RE, et al. Adjunctive cognitive remediation for schizophrenia using yoga: an open, non‐randomised trial. Acta Neuropsychiatr. 2012;24:91–100.10.1111/j.1601-5215.2011.00587.xSearch in Google Scholar PubMed PubMed Central
[27] Bhargav H, Nagendra HR, Gangadhar BN, Nagarathna R. Frontal hemodynamic responses to high frequency yoga breathing in schizophrenia: a functional near-infrared spectroscopy study. Front Psychiatry. 2014;5:2910.3389/fpsyt.2014.00029Search in Google Scholar
[28] Streeter CC, Gerbarg PL, Saper RB, Ciraulo DA, Brown RP. Effects of yoga on the autonomic nervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder. Med Hypotheses. 2012;78:571–9.10.1016/j.mehy.2012.01.021Search in Google Scholar PubMed
[29] Naveen GH, Thirthalli J, Rao MG, Varambally S, Christopher R, Gangadhar BN. Positive therapeutic and neurotropic effects of yoga in depression: a comparative study. Indian J Psychiatry. 2013;55:S400.10.4103/0019-5545.116313Search in Google Scholar PubMed PubMed Central
© 2019 Walter de Gruyter GmbH, Berlin/Boston
